Vol. 33. Núm. S2.
Páginas 9-39 (Abril 2026)

Tratamiento Anticoagulante Oral

Jordi Altirriba VivesaGabriela Simona EnebErik Johansson BarroncClara Ortí SegarradMaricel Subirà Casellesc
Doi : https://10.1016/j.fmc.2026.04.001
Opciones

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
I.C. Van Gelder, M. Rienstra, K.V. Bunting, R. Casado-Arroyo, V. Caso, H.J.G.M. Crijns, et al.
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).
Eur Heart J., (2024), 45 pp. 3314-3414
[2]
J.A. Joglar, M.K. Chung, A.L. Armbruster, E.J. Benjamin, J.Y. Chyou, E.M. Cronin, et al.
2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Circulation., (2024), 149 pp. e1-e156
[3]
J.C. Reverter, D. Tàssies, C. Alba, N. Pérez, P. Olivera, G. Ene, et al.
Protocol de maneig de la TAO amb fàrmacs ACO.
Consorci Sanitari de Barcelona, Àrea Integral de Salut Barcelona Esquerra (AISBE);, (2023),
[4]
Agencia Española de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terapéutico IPT-230/V5/08022024: Criterios y recomendaciones generales para el uso de los anticoagulantes orales directos (ACOD) en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular (FANV). Madrid: AEMPS; 2024. Disponible en: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/2024/IPT-230-ACOD-FANV.pdf.
[5]
R.A. Byrne, X. Rossello, J.J. Coughlan, E. Barbato, C. Berry, A. Chieffo, et al.
2023 ESC Guidelines for the management of acute coronary syndromes.
Eur Heart J., (2023), 44 pp. 3720-3826
[6]
C. Vrints, F. Andreotti, K.C. Koskinas, X. Rosello, M. Adamo, J. Ainslie, et al.
2024 ESC Guidelines for the management of chronic coronary syndromes.
Eur Heart J., (2024), 45 pp. 3415-3537
[7]
F. Praz, M.A. Borger, J. Lanz, M. Marin-Cuartas, A. Abreu, M. Adamo, et al.
2025 ESC/EACTS Guidelines for the management of valvular heart disease.
Eur Heart J., (2025), 46 pp. 4635-4736
[8]
J. Altirriba i Vives, J.A. Vallès Callol.
Diagnòstic i tractament de la trombosi venosa profunda.
Societat Catalana de Medicina Familiar i Comunitària (CAMFiC);, (2024),
[9]
L. Mazzolai, W. Ageno, A. Alatri, R. Bauersachs, C. Becattini, M. Brodmann, et al.
Second consensus document on diagnosis and management of acute deep vein thrombosis: Updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function.
Eur J Prev Cardiol., (2022), 29 pp. 1248-1263
[10]
S.K. Kakkos, M. Gohel, N. Baekgaard, R. Bauersachs, S. Bellmunt-Montoya, S.A. Black, et al.
Editor's choice - European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis.
Eur J Vac Endovasc Surg., (2021), 61 pp. 9-82
[11]
L. Mazzolai, V. Aboyans, W. Ageno, G. Agnelli, A. Alatri, R. Bauersachs, et al.
Diagnosis and management of acute deep vein thrombosis: A joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function.
Eur Heart J., (2018), 39 pp. 4208-4218
[12]
A. Dubois.
Trombosis venosa profunda de extremidades inferiores.
Fisterra, (2022),
[13]
R. Villa Estébanez, Ó. Veiras del Río.
Trombosis venosa profunda.
AMF., (2021), 17 pp. 4-13
[14]
Agencia Española de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terapéutico IPT-229/V1/08022024: Criterios y recomendaciones generales para el uso de los anticoagulantes orales directos (ACOD) en el tratamiento y prevención secundaria del tromboembolismo venoso (TEV) en adultos. Madrid: AEMPS; 2024. Disponible en: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/2024/IPT-229-ACOD-TEV.pdf.
[15]
S.V. Konstantinides, G. Meyer, C. Becattini, H. Bueno, G.J. Geersing, V.P. Harjoa, et al.
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).
Eur Heart J., (2020), 41 pp. 543-603
[16]
Servicio Navarro de, Salud-Osasunbidea.
Anticoagulación oral (TAO) en el Servicio Navarro de Salud-Osasunbidea.
Servicio de Efectividad y Seguridad Asistencial, (2025),
[17]
J.E. Ansell.
Oral anticoagulant therapy--50 years later.
Arch Intern Med., (1993), 153 pp. 586-596
[18]
A. Holbrook, S. Schulman, D.M. Witt, P.O. Vandvik, J. Fish, M.J. Kovacs, et al.
Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Chest., (2012), 141 pp. e152S-e184S
[19]
T. Salmonson, J.M. Dogné, H. Janssen, J. Garcia Burgos, P. Blake.
Non-vitamin-K oral anticoagulants and laboratory testing: Now and in the future: Views from a workshop at the European Medicines Agency (EMA).
Eur Heart J Cardiovasc Pharmacother., (2017), 3 pp. 42-47
[20]
A. Gómez-Outes, P. Alcubilla, G. Calvo-Rojas, A.I. Terleira-Fernández, M.L. Suárez-Gea, R. Lecumberri, et al.
Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants.
J Am Coll Cardiol., (2021), 77 pp. 2987-3001
[21]
N. Ferri, E. Colombo, M. Tenconi, L. Baldessin, A. Corsini.
Drug-drug interactions of direct oral anticoagulants (DOACs): From pharmacological to clinical practice.
Pharmaceutics., (2022), 14 pp. 1120
[22]
S.R. Vazquez.
Drug-drug interactions in an era of multiple anticoagulants: A focus on clinically relevant drug interactions.
Blood., (2018), 132 pp. 2230-2239
[23]
B.S. Wiggins, D.L. Dixon, R.R. Neyens, R.L. Page 2nd, T.J. Gluckman.
Select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week.
J Am Coll Cardiol., (2020), 75 pp. 1341-1350
[24]
J. Altirriba, P. Aparicio.
Anticoagulación oral en Atención Primaria.
Rev Esp Sanid Penit., (2017), 19 pp. 28-44
[25]
R.M. Crawley, R.L. Anderson.
Prevention and treatment of bleeding with direct oral anticoagulants.
Drugs., (2020), 80 pp. 1293-1308
[26]
G.F. Tomaselli, K.W. Mahaffey, A. Cuker, P.P. Dobesh, J.U. Doherty, J.W. Eikelboom, et al.
2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: A report of the American College of Cardiology Solution Set Oversight Committee.
J Am Coll Cardiol., (2020), 76 pp. 594-622
[27]
A. Koutsoumpelis, C. Argyriou, K.M. Tasopoulou, E.I. Georgakarakos, G.S. Georgiadis.
Novel oral anticoagulants in peripheral artery disease: Current evidence.
Curr Pharm Des., (2018), 24 pp. 4511-4515
[28]
W. Ageno, B. Caramelli, M.P. Donadini, L. Girardi, N. Riva.
Changes in the landscape of anticoagulation: A focus on direct oral anticoagulants.
Lancet Haematol., (2024), 11 pp. e938-e950
[29]
M.P. Bonaca, R.M. Bauersachs, S.S. Anand, E.S. Debus, M.R. Nehler, M.R. Patel, et al.
Rivaroxaban in peripheral artery disease after revascularization.
N Engl J Med., (2020), 382 pp. 1994-2004
[30]
J.M. Rivera-Caravaca, A. Camelo-Castillo, I. Ramírez-Macías, P. Gil-Pérez, C. López-García, M.A. Esteve-Pastor, et al.
Antithrombotic therapy in patients with peripheral artery disease: A focused review on oral anticoagulation.
Int J Mol Sci., (2021), 22 pp. 7113
[31]
A. Bejjani, B. Bikdeli.
Direct oral anticoagulants: Quick primer on when to use and when to avoid.
Thromb Haemost., (2025), 125 pp. 611-617
[32]
N. Chan, M. Sobieraj-Teague, J.W. Eikelboom.
Direct oral anticoagulants: Evidence and unresolved issues.
Lancet., (2020), 396 pp. 1767-1776
[33]
D.P. Ebertz, S. Bose, J.A. Smith, A.L. Sarode, R.N. Ambani, J.S. Cho, et al.
Use of direct-acting oral anticoagulants associated with improved survival and bypass graft patency compared with warfarin after infrageniculate bypass.
J Vasc Surg., (2023), 77 pp. 1453-1461
[34]
S. Kumar, E. Lim, A. Covic, P. Verhamme, C.P. Gale, A.J. Camm, et al.
Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week.
J Am Coll Cardiol., (2019), 74 pp. 2204-2215
[35]
L. Tapoi, C. Ureche, R. Sascau, S. Badarau, A. Covic.
Atrial fibrillation and chronic kidney disease conundrum: An update.
J Nephrol., (2019), 32 pp. 909-917
[36]
O. Königsbrügge, C. Ay.
Atrial fibrillation in patients with end-stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation.
Res Pract Thromb Haemost., (2019), 3 pp. 578-588
[37]
S.M. Jang, K. Bahjri, H. Tran.
Safety and efficacy of direct oral anticoagulants for atrial fibrillation in patients with renal impairment.
Pharmacy (Basel)., (2020), 8 pp. 30
[38]
P. Vranckx, M. Valgimigli, H. Heidbuchel.
The significance of drug-drug and drug-food interactions of oral anticoagulation.
Arrhythm Electrophysiol Rev., (2018), 7 pp. 55-61